# A Study of MT027 in Patients with Pleural Malignant Tumors

> **NCT06726564** · PHASE1 · RECRUITING · sponsor: **Suzhou Maximum Bio-tech Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumor
- Malignant Pleural Effusion
- Pleura Carcinoma
- Pleural Mesothelioma
- Pleural Malignant Mesothelioma
- Pleural Metastases

## Interventions

- **DRUG:** MT027 cells suspension

## Key facts

- **NCT ID:** NCT06726564
- **Lead sponsor:** Suzhou Maximum Bio-tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-15
- **Primary completion:** 2026-05
- **Final completion:** 2029-02
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06726564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06726564, "A Study of MT027 in Patients with Pleural Malignant Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06726564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*